6月5日,普利制药宣布,公司于近日收到了白俄罗斯药监局(Ministry of Health of the Republic of Belarus)签发的钆布醇注射液的上市许可,获批2个规格1mmol/ml,7.5ml/瓶、15ml/瓶,标志着普利制药具备在白俄罗斯销售钆布醇注射液的资格。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.